Label and off-label treatment of dermatological diseases with JAK and TYK inhibitors

Janus kinase (JAK) inhibitors are a class of targeted therapies that have revolutionized the management of various inflammatory and autoimmune diseases, including dermatological ones. This narrative review explores their mechanisms, clinical applications, and safety profiles, with a focus on both labeled and off-label uses. JAK inhibitors, such as Baricitinib, Upadacitinib, and Abrocitinib, have shown substantial efficacy in conditions like alopecia areata, atopic dermatitis, and vitiligo. The selective inhibition of specific JAK isoforms underpins their therapeutic effects, with unique profiles influencing both efficacy and safety. Topical JAK inhibitors, such as Ruxolitinib cream, provides a localized approach, minimizing systemic exposure and associated risks. However, the class is not without limitations; adverse effects, including infections and thromboembolic events, necessitate careful patient selection and monitoring. Furthermore, findings from off-label applications often rely on limited evidence, emphasizing the need for robust clinical trials to validate these uses. This review also identifies several limitations, including potential selection bias and a reliance on existing literature, which restrict insights into ongoing and unpublished research. Despite these challenges, JAK inhibitors remain a cornerstone of dermatological treatment, offering new avenues for personalized care. Future research should prioritize biomarker-driven approaches, long-term safety assessments, and the development of agents with reduced off-target effects. As our understanding of JAK-STAT signaling advances, these therapies hold immense promise for expanding the therapeutic landscape in dermatology.